Mayo Clinic and Whole Biome Announce Collaboration
Whole Biome, Inc. is co-developing microbiome targeted diagnostic testing with the Mayo Clinic Center for Individualized Medicine, beginning in Women’s Health, with a focus on preterm labor. Preterm birth is the most common cause of infant death and is the leading cause of long-term disability in children, according to the National Institutes of Health. Many preterm births may be delayed or prevented with microbiome-based testing and intervention, according to Mayo Clinic experts.
Whole Biome Listed as Top Artificial Intelligence Company to Watch
"The field of medical AI is buzzing. More and more companies set the purpose to disrupt healthcare with the help of artificial intelligence. Here, I collected the biggest names currently on the market ranging from start-ups to tech giants to keep an eye on in the future. Speeding up the process of drug development and making it more cost-effective through AI technologies would have an enormous effect on today’s healthcare."
Whole Biome Wins Buzz of Bio
“I am proud to feature these companies as our Buzz of BIO winners and provide them with the exposure and connections that come with presenting at the BIO Investor Forum” said Jim Greenwood, BIO President & CEO
Whole Biome Listed in "Top 20 Companies to Watch"
"There is a lot of buzz around the San Francisco company which is developing microbiome diagnostics and drugs ... Its tests hope to generate a microbiome profile that helps prevent or treat various conditions."
Whole Biome Interview Highlighted at BIO Conference
BIO Center interview with Colleen Cutcliffe on the microbiome space: challenges, promises and investment opportunities.